Drug Trial Radar · NCT00208312
ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Last checked: Nov 20, 2026Latest source record: Nov 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
787
Actual
Start
Apr 2004
Primary completion
Jun 2005
Study completion Jun 2005
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Astellas Pharma US, Inc.
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist, the receptor responsible for coronary vasodilation, and is being studied for potential use as a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible myocardial perfusion defects.
Conditions
- Coronary Artery Disease
Interventions
RegadenosonDrug
0.4 mg, bolus intravenous injection
AdenosineDrug
0.14 mg/kg/min for 6 minutes, intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-inferiority of regadenoson to Adenoscan for use in SPECT myocardial perfusion imaging in assessing reversible perfusion defectsTime frame: After radiopharmaceutical administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Multiple study locations (see Central Contact); CV Therapeutics, Inc.
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.